

Technologies for digital patient finding

(and trial matching too)

Richard Child
Director, Health Research Ecosystem,
Applied Data Science Centre, IQVIA

Problems



Manually intensive

- High burden on Research Coordinators
- Many feasibility requests and repeated searches
- Requires harmony with IT colleagues



EHR systems not designed for searching

- Basic searches by ICD-10 against structured data
- Many fragmented EHR systems
- Data buried in unstructured notes, reports, charts



Patient Finding a major challenge for studies

- Enrollment targets missed at 48% of centers ¹
- Inclusion and Exclusion criteria are more precise
- Studies are delayed or unable to reach primary endpoints – delaying potential new options for Patients



¹ Getz, K. Changing Drug Development Landscape and its Anticipated Impact on R&D Operations. Accessed September 21, 20162

Recent improvements



Data interoperability

- HL7 FHIR rapidly adopted
Interop Santé France, NHS Digital UK
- Data becoming recognised by EHR vendors as Controlled by the Patient and Centre!



Text Mining & Natural Language Processing

- Level 1 - Ontology assisted search, including synonyms
- Level 2 - Parsing : Condition, Labs, Stage, Grade, ECOG
- Level 3 - Contextual: Family vs. Patient history, Negations: "No", "Does not", "Possible"



Digital Patient Finding tools

- Designed for all users, not just IT data analysts
- Collation of data from multiple EHRs within a centre



USA – Patient Access Rule, Non-blocking rule



21st Century Cures Act

Signed into law in December 2016, defined interoperability and prohibited information blocking. The Cures Act gave HHS further ability to propose and enact regulations.




ONC “Cures Final Rule”

Released March 2020, details FHIR-based Health IT interoperability requirements and exceptions to information blocking



Assessment and Plan of Treatment	Laboratory <ul style="list-style-type: none">• Tests• Values/Results	Provenance *NEW <ul style="list-style-type: none">• Author• Author Time Stamp• Author Organization
Care Team Members	Medications <ul style="list-style-type: none">• Medications• Medication Allergies	Smoking Status
Clinical Notes *NEW <ul style="list-style-type: none">• Consultation Note• Discharge Summary Note• History & Physical• Imaging Narrative• Laboratory Report Narrative• Pathology Report Narrative• Procedure Note• Progress Note	Patient Demographics <ul style="list-style-type: none">• First Name• Last Name• Previous Name• Middle Name (including middle initial)• Suffix• Birth Sex• Date of Birth• Race• Ethnicity• Preferred Language• Address *NEW• Phone Number *NEW	Unique Device Identifier(s) for a Patient's Implantable Device(s)
Goals <ul style="list-style-type: none">• Patient Goals	Problems	Vital Signs <ul style="list-style-type: none">• Diastolic Blood Pressure• Systolic Blood Pressure• Body Height• Body Weight• Heart Rate• Respiratory rate• Body Temperature• Pulse oximetry• Inhaled oxygen concentration• Pediatric Vital Signs *NEW<ul style="list-style-type: none">- BMI percentile per age and sex for youth 2-20- Weight for age per length and sex- Occipital-frontal circumference for children < 3 years old
Health Concerns	Procedures	
Immunizations		

Natural Language Processing (NLP)



Admitting Note

James Anderson, a 51 year old man with past history of hypertension and osteoarthritis, complains of tiredness, daytime somnolence, and frequently waking up at night to pass urine. He has a sedentary lifestyle with a high fat and high carbohydrates diet. He is a former smoker of 2 packs a day, quit 10 years ago. Patient states he lives alone, and is under a lot of stress. Lately, he has been drinking approximately 6 beers a day. In the past 4 years has become significantly overweight, and has had increased problems walking upstairs, he has a current body mass index of 38.2 kg/m² and BP of 140/90. Following a visit to his PCP, he was diagnosed with type 2 diabetes (T2D), based on the following diagnosis criteria: HbA_{1c} > 48 mmol/mol; fasting glucose concentration > 7.0 mmol/l; 2-hour post 75gram glucose load (oral glucose tolerance test) glucose concentration > 11.1 mmol/l (screening result provided below)

Additionally, based on the high-risk profile for other metabolic co-morbid conditions associated with T2D further assessments included:

Testing parameter/Time frame	Normal	Patient results
Blood glucose level measurement (HbA _{1c})/mmol/mol and % HbA _{1c}	Optimum level HbA _{1c} < 48 mmol/mol and between % HbA _{1c} 6.5% and 7.5%	74.9 mmol/mol and % HbA _{1c} 9%
2-hour post 75gram glucose load (oral glucose tolerance test)	> 11.1 mmol/l	15.1 mmol/l
K	3.6 – 5.2 mmol/l	4.5 mmol/l
Na	135-145 mEq/L	139 mEq/L
Total Cholesterol	≤ 5.0 mmol/L or lower	6.5 mmol/L
Kidney function testing (Urinary albumin)	<30 mg/g	26 mg/g

His current medications include: OTC Advil prn; 40mg of Lotensin daily. He was prescribed metformin 500mg three times a day implemented in combination with appropriate lifestyle and dietary advice and intervention. He was also prescribed a lipid lowering agent and antihypertension agent and asked to return in 3 months.

He missed his 3 month appointment on 24 November 2014 and follow-up at 6 month on 2015/02/28 showed an HbA_{1c} increased to 91.3 mmol/mol/HbA_{1c} 10.5%, increased weigh to 41.2 kg/m² along with minimal increases in blood pressure and cholesterol.

Diseases

Text	Normalized Value
Type 2 Diabetes	Diabetes Mellitus, Type 2
T2D	SNOMEDid 44054006

Symptoms

Text	Normalized Value
Sleepiness	Fatigue/tiredness
Daytime Somnolence	
Frequently waking up at night to pass urine	Nocturia Urinary frequency

Social Determinants

Text	Normalized Value
Former smoker	Ex smoker
Quit 10 years ago	
Problems walking	Ambulatory Status: walking difficulty
Lot of stress	High levels of stress/Stress
He lives alone	Social Isolation
Missed his 3 month appointment	Did not attend

Demographics

Text	Normalized Value
51 year old	51y
man	Male

Dates

Text	Normalized Value
24th November 2014	20141124
2015/02/28	20150228

Measurements

Text	Normalized Value
Body mass index of 38.2 kg/m ²	BMI 38.2 kg/m ²
15.1 mmol/l	15.1 mmol/l

Medications

Text				
On Metformin 0.5g PO three times a day				
Normalized value				
Medications				
Drug Name	Dose	Unit	Route	Frequency
Metformin	500	mg	Oral	TID

Illustrative examples of modern Patient finding tools



Inclusion

Patients in my population **must** have of the following terms

Diagnoses
Diagnosis code Maligne neoplasma van prostaat, benign...
Stage IV

AND

PSA
Name PSA
Numeric value ≥ 2

AND

TNM
Name TNM T
Textual value T2

AND

Patient Information (Demographics)
Sex Male
Age ≤ 95 years

AND

Gleason
Name Gleason sum
Numeric value 6 - 9

Patient cohorts

Search results (610) Included (3) Excluded (1)

Criteria selection

Manually add patients

Filters

#	Patient Pseudo ID	Sex	Age	Birth year
1	0300_9380-37	Male	44	1976
2	0301_554-1244	Male	61	1960
3	0301_554-13509	Male	72	1949
4	0301_554-14273	Male	74	1947
5	0301_554-1905	Male	64	1954
6	0301_554-9663	Male	53	1968


Illustrative examples of modern Patient finding tools



Measurements 1 results Sorted by Start date Newest (descending)			
Name	Numeric value	Unit	Start date
<p>PSA</p> <p>lasmosis such as night sweats or fatigue. Talk about severe bosom fibrillation. Especially gut. TURP because of Kortekaas, Pain: no, Fatigue: -, PSA 5.3 and Gluc 6.6 values of pat are just within the norm, sometimes radiates over the flank of the knee, complaints about increased stacking after an MRI,</p>	5.30		01-05-2018 02:00
<p>TNM T</p> <p>tsyndrome Admission with heels and myocardial infarction Increased lymphoma risk related to Physical examination</p> <p>Conclusion: could be liver tumor TNM: prostate carcinoma (cT2-3aNOMx)</p> <p>Sincerely, Doctor Cool</p>			13-09-2019 02:00

**But I know all my Patients
and need to find trials!**





- Main EHR
- Oncology EHR
- E-Prescribing
- Lab
- Pathology

- ✓ Structured
- ✓ Unstructured

Patient Data



Trial Matching →
1x Patient to many Trials

- Patient search engine
- Trial lookup

- Automation of
Patients ← → Studies




← Patient Finding
1x Trial to many Patients

Protocols

- Eligibility Criteria
- Many Studies
- Many Centres




Road from digital Patient Finding to Trial Matching



Collaboration and Community



Patients and Studies in a Cancer alliance, or even region / national / Europe



Patients and Studies at My Centre

- Visibility of all Studies by colleagues
- Find Patients under care of others

- My Centre may be at capacity, refer Patients to other Centres
- Find Studies with my region
- Share digitised protocol with other Centres and find Patients

Patients and Studies I know

- Digitise protocols for my studies
- Find Patients for my studies only

Benefits



Benefits of digital Patient Finding



DATA VISIBILITY

- MORE studies & patients surfaced
- Not solely dependent on investigator knowledge

FINANCIAL


- Increased research revenues

OPERATIONAL EFFICIENCY

- Reduce manual searches
- Saves time & effort
- Focus on *eligible* patients

DIVERSITY AND INCLUSION

- Equitable access to studies
- Link with Social Determinants of Health



BEHIND THE FIREWALL

- GDPR privacy by design
- Share digitised protocols and anonymised results, not data

PATIENT

- Avoid unnecessary appointments

FEASIBILITY

- Feedback to sponsor on protocol

USE BEYOND STUDIES

- Cohort / Patient finding for Centre purposes


Digitally-enabled Site ID

CASE STUDY
Phase II:
cholangiocarcinoma




Higher recruitment rate

Enrollment
(p/s/m = patient / site / month)




Lower screen failure rate

Rate of screen failures



Fewer non-enrollers

Non-enrolling sites




Recruitment completed ~6 months ahead of schedule

Looking forwards




Common problems and needs




Many needs are shared – we need to direct investment not just to benefit Trials, but also Real World Evidence generation and Patient care

Common problems and needs




Looking forwards



AI Machine Learning enabled Patient Finding




1 Assemble and analyze the often complex medical history of target patients




2 Use Machine Learning to identify unique patterns in target patients' medical history PRIOR to Diagnosis or Event



3 Deploy learnings to identify specific target patient populations



Bad AI?



Integrating clinical expertise and machine learning

Case study to identify undiagnosed patients with rare disease showed substantially better results using a hybrid Clinical-AI method in comparison to fully data-driven AI or KOL based knowledge alone



BACKGROUND

- Tuberous sclerosis complex (TSC) is a rare disease with a prevalence of 1 in 15,000
- TSC patients develop Benign multi-system tumours lead to epilepsy, cognitive impairment, kidney failure, etc.
- Manifestations typically start in childhood but correct diagnosis can be delayed into adulthood

CHALLENGE

A client was interested in understanding whether early disease detection algorithms could be used to find undiagnosed patients with TSC

IMPLEMENTATION AND IMPACT

IQVIA conducted a UK study leveraging data from primary (CPRD) and specialist (HES) care. Data covered ~5m patients. **Four algorithms were developed:**

1. KOL-based rules



Rules based on clinical KOL interviews

1 in ~25 

patients predicted to have TSC go on to receive a diagnosis of TSC

2. Conventional Statistics



Standard statistical / epidemiology approach based on logistic regression

1 in ~13 

patients predicted to have TSC go on to receive a diagnosis of TSC

3. Data-driven AI



Support vector machine based on all available features

1 in ~6 

patients predicted to have TSC go on to receive a diagnosis of TSC

4. Hybrid Clinical-AI



Support vector machine incorporating clinically driven feature engineering

1 in ~4 

patients predicted to have TSC go on to receive a diagnosis of TSC

AI combined with clinical knowledge performed best

- 2.5 times better than standard epidemiological approach
- 5 times better than rules based on KOL knowledge

Public + Private, Research + Care – DATA-CAN



Our aim is to improve care and outcomes for people with cancer by making high quality health data more accessible for cancer researchers and health professionals

Making high-quality datasets available via an online portal - the Health Data Research Innovation Gateway

Working with patients and the public to make sure that data is used in a transparent and responsible way that benefits the NHS, patients and society

Collecting and using 'real-time' cancer data from the NHS to help health services identify issues and respond to events, such as COVID-19

Supporting more patients into cancer clinical trials through the development of trial matching software

UK wide partnership of six founding organisations with plans to expand



DigiCore

Thank you

